nodes	percent_of_prediction	percent_of_DWPC	metapath
Irinotecan—lung cancer—testicular cancer	0.234	1	CtDrD
Irinotecan—Topoisomerase Inhibitors—Etoposide—testicular cancer	0.224	0.43	CiPCiCtD
Irinotecan—Topoisomerase Inhibitors—Epirubicin—testicular cancer	0.154	0.296	CiPCiCtD
Irinotecan—Topoisomerase Inhibitors—Doxorubicin—testicular cancer	0.143	0.274	CiPCiCtD
Irinotecan—ABCC1—Dactinomycin—testicular cancer	0.0129	0.0703	CbGbCtD
Irinotecan—ABCC1—Epirubicin—testicular cancer	0.00938	0.0509	CbGbCtD
Irinotecan—UGT1A1—Etoposide—testicular cancer	0.00889	0.0483	CbGbCtD
Irinotecan—ABCG2—Dactinomycin—testicular cancer	0.00867	0.0471	CbGbCtD
Irinotecan—ABCC1—Vinblastine—testicular cancer	0.00811	0.0441	CbGbCtD
Irinotecan—CYP3A7—Ifosfamide—testicular cancer	0.00756	0.0411	CbGbCtD
Irinotecan—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.00756	0.0411	CbGbCtD
Irinotecan—ABCC1—Etoposide—testicular cancer	0.00731	0.0397	CbGbCtD
Irinotecan—CYP2B6—Ifosfamide—testicular cancer	0.0072	0.0391	CbGbCtD
Irinotecan—BCHE—Cisplatin—testicular cancer	0.00707	0.0384	CbGbCtD
Irinotecan—ABCC2—Carboplatin—testicular cancer	0.00644	0.035	CbGbCtD
Irinotecan—ABCC2—Vinblastine—testicular cancer	0.006	0.0326	CbGbCtD
Irinotecan—ABCG2—Carboplatin—testicular cancer	0.00582	0.0316	CbGbCtD
Irinotecan—CYP3A5—Ifosfamide—testicular cancer	0.00567	0.0308	CbGbCtD
Irinotecan—ABCC2—Cisplatin—testicular cancer	0.0055	0.0299	CbGbCtD
Irinotecan—ABCC2—Etoposide—testicular cancer	0.00541	0.0294	CbGbCtD
Irinotecan—ABCC1—Doxorubicin—testicular cancer	0.00498	0.0271	CbGbCtD
Irinotecan—ABCG2—Cisplatin—testicular cancer	0.00498	0.027	CbGbCtD
Irinotecan—ABCG2—Etoposide—testicular cancer	0.00489	0.0266	CbGbCtD
Irinotecan—ABCC1—Methotrexate—testicular cancer	0.00483	0.0262	CbGbCtD
Irinotecan—SLCO1B1—Methotrexate—testicular cancer	0.00407	0.0221	CbGbCtD
Irinotecan—ABCC2—Doxorubicin—testicular cancer	0.00369	0.02	CbGbCtD
Irinotecan—ABCC2—Methotrexate—testicular cancer	0.00357	0.0194	CbGbCtD
Irinotecan—CYP2B6—Cisplatin—testicular cancer	0.0035	0.019	CbGbCtD
Irinotecan—ABCG2—Doxorubicin—testicular cancer	0.00334	0.0181	CbGbCtD
Irinotecan—ABCG2—Methotrexate—testicular cancer	0.00323	0.0176	CbGbCtD
Irinotecan—ABCB1—Dactinomycin—testicular cancer	0.00312	0.017	CbGbCtD
Irinotecan—CYP3A5—Etoposide—testicular cancer	0.00271	0.0147	CbGbCtD
Irinotecan—CYP2B6—Doxorubicin—testicular cancer	0.00235	0.0127	CbGbCtD
Irinotecan—ALB—Methotrexate—testicular cancer	0.00223	0.0121	CbGbCtD
Irinotecan—CYP3A4—Ifosfamide—testicular cancer	0.00221	0.012	CbGbCtD
Irinotecan—ABCB1—Vinblastine—testicular cancer	0.00196	0.0106	CbGbCtD
Irinotecan—ABCB1—Cisplatin—testicular cancer	0.00179	0.00975	CbGbCtD
Irinotecan—ABCB1—Etoposide—testicular cancer	0.00176	0.00958	CbGbCtD
Irinotecan—ABCB1—Doxorubicin—testicular cancer	0.0012	0.00653	CbGbCtD
Irinotecan—CYP3A4—Vinblastine—testicular cancer	0.00117	0.00637	CbGbCtD
Irinotecan—ABCB1—Methotrexate—testicular cancer	0.00117	0.00633	CbGbCtD
Irinotecan—CYP3A4—Etoposide—testicular cancer	0.00106	0.00574	CbGbCtD
Irinotecan—TOP1MT—gonad—testicular cancer	0.000763	0.0742	CbGeAlD
Irinotecan—CYP3A4—Doxorubicin—testicular cancer	0.000721	0.00391	CbGbCtD
Irinotecan—TOP1MT—female gonad—testicular cancer	0.00062	0.0603	CbGeAlD
Irinotecan—TOP1—seminal vesicle—testicular cancer	0.000557	0.0541	CbGeAlD
Irinotecan—TOP1MT—testis—testicular cancer	0.00055	0.0534	CbGeAlD
Irinotecan—CES2—seminal vesicle—testicular cancer	0.000505	0.0491	CbGeAlD
Irinotecan—TOP1MT—lymph node—testicular cancer	0.000398	0.0387	CbGeAlD
Irinotecan—CES2—gonad—testicular cancer	0.000365	0.0355	CbGeAlD
Irinotecan—TOP1—female gonad—testicular cancer	0.000327	0.0318	CbGeAlD
Irinotecan—SLC22A3—embryo—testicular cancer	0.000307	0.0299	CbGeAlD
Irinotecan—CES2—female gonad—testicular cancer	0.000297	0.0288	CbGeAlD
Irinotecan—TOP1—testis—testicular cancer	0.00029	0.0282	CbGeAlD
Irinotecan—SLC22A3—seminal vesicle—testicular cancer	0.000289	0.0281	CbGeAlD
Irinotecan—CES2—testis—testicular cancer	0.000263	0.0256	CbGeAlD
Irinotecan—CES1—female gonad—testicular cancer	0.000244	0.0237	CbGeAlD
Irinotecan—ABCC1—seminal vesicle—testicular cancer	0.000239	0.0232	CbGeAlD
Irinotecan—CES1—testis—testicular cancer	0.000217	0.0211	CbGeAlD
Irinotecan—ACHE—testis—testicular cancer	0.000217	0.0211	CbGeAlD
Irinotecan—TOP1—lymph node—testicular cancer	0.00021	0.0204	CbGeAlD
Irinotecan—SLC22A3—gonad—testicular cancer	0.000209	0.0203	CbGeAlD
Irinotecan—BCHE—seminal vesicle—testicular cancer	0.000204	0.0199	CbGeAlD
Irinotecan—ABCG2—seminal vesicle—testicular cancer	0.000198	0.0192	CbGeAlD
Irinotecan—CES2—lymph node—testicular cancer	0.000191	0.0185	CbGeAlD
Irinotecan—SLC22A3—female gonad—testicular cancer	0.000169	0.0165	CbGeAlD
Irinotecan—ACHE—lymph node—testicular cancer	0.000157	0.0153	CbGeAlD
Irinotecan—CES1—lymph node—testicular cancer	0.000157	0.0153	CbGeAlD
Irinotecan—ALB—testis—testicular cancer	0.000151	0.0146	CbGeAlD
Irinotecan—SLC22A3—testis—testicular cancer	0.00015	0.0146	CbGeAlD
Irinotecan—ABCC2—testis—testicular cancer	0.000141	0.0137	CbGeAlD
Irinotecan—ABCC1—female gonad—testicular cancer	0.00014	0.0136	CbGeAlD
Irinotecan—CYP2B6—gonad—testicular cancer	0.000132	0.0128	CbGeAlD
Irinotecan—ABCC1—testis—testicular cancer	0.000124	0.0121	CbGeAlD
Irinotecan—ABCG2—female gonad—testicular cancer	0.000116	0.0113	CbGeAlD
Irinotecan—ALB—lymph node—testicular cancer	0.000109	0.0106	CbGeAlD
Irinotecan—SLC22A3—lymph node—testicular cancer	0.000109	0.0106	CbGeAlD
Irinotecan—CYP3A5—female gonad—testicular cancer	0.000108	0.0105	CbGeAlD
Irinotecan—BCHE—testis—testicular cancer	0.000106	0.0103	CbGeAlD
Irinotecan—ABCB1—embryo—testicular cancer	0.000104	0.0101	CbGeAlD
Irinotecan—ABCG2—testis—testicular cancer	0.000103	0.01	CbGeAlD
Irinotecan—ABCC2—lymph node—testicular cancer	0.000102	0.00994	CbGeAlD
Irinotecan—ABCB1—seminal vesicle—testicular cancer	9.74e-05	0.00947	CbGeAlD
Irinotecan—CYP2B6—testis—testicular cancer	9.49e-05	0.00923	CbGeAlD
Irinotecan—ABCC1—lymph node—testicular cancer	9.01e-05	0.00876	CbGeAlD
Irinotecan—BCHE—lymph node—testicular cancer	7.72e-05	0.0075	CbGeAlD
Irinotecan—ABCG2—lymph node—testicular cancer	7.46e-05	0.00725	CbGeAlD
Irinotecan—ABCB1—gonad—testicular cancer	7.04e-05	0.00684	CbGeAlD
Irinotecan—ABCB1—female gonad—testicular cancer	5.72e-05	0.00556	CbGeAlD
Irinotecan—ABCB1—testis—testicular cancer	5.07e-05	0.00493	CbGeAlD
Irinotecan—ABCB1—lymph node—testicular cancer	3.68e-05	0.00358	CbGeAlD
Irinotecan—Thrombocytopenia—Etoposide—testicular cancer	3.5e-05	0.000698	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Methotrexate—testicular cancer	3.5e-05	0.000698	CcSEcCtD
Irinotecan—Dyspnoea—Cisplatin—testicular cancer	3.48e-05	0.000694	CcSEcCtD
Irinotecan—Hyperhidrosis—Etoposide—testicular cancer	3.46e-05	0.000689	CcSEcCtD
Irinotecan—Pancreatitis—Epirubicin—testicular cancer	3.46e-05	0.000689	CcSEcCtD
Irinotecan—Orthostatic hypotension—Doxorubicin—testicular cancer	3.45e-05	0.000687	CcSEcCtD
Irinotecan—Hypokalaemia—Doxorubicin—testicular cancer	3.43e-05	0.000684	CcSEcCtD
Irinotecan—Angina pectoris—Epirubicin—testicular cancer	3.43e-05	0.000684	CcSEcCtD
Irinotecan—Anorexia—Etoposide—testicular cancer	3.41e-05	0.000679	CcSEcCtD
Irinotecan—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	3.4e-05	0.000677	CcSEcCtD
Irinotecan—Decreased appetite—Cisplatin—testicular cancer	3.39e-05	0.000676	CcSEcCtD
Irinotecan—Diarrhoea—Dactinomycin—testicular cancer	3.38e-05	0.000674	CcSEcCtD
Irinotecan—Pneumonia—Methotrexate—testicular cancer	3.38e-05	0.000673	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Cisplatin—testicular cancer	3.37e-05	0.000672	CcSEcCtD
Irinotecan—Vomiting—Bleomycin—testicular cancer	3.37e-05	0.000671	CcSEcCtD
Irinotecan—Hypotension—Etoposide—testicular cancer	3.34e-05	0.000666	CcSEcCtD
Irinotecan—Rash—Bleomycin—testicular cancer	3.34e-05	0.000666	CcSEcCtD
Irinotecan—Pain—Cisplatin—testicular cancer	3.34e-05	0.000665	CcSEcCtD
Irinotecan—Dermatitis—Bleomycin—testicular cancer	3.34e-05	0.000665	CcSEcCtD
Irinotecan—Hypersensitivity—Ifosfamide—testicular cancer	3.34e-05	0.000665	CcSEcCtD
Irinotecan—Renal failure—Methotrexate—testicular cancer	3.3e-05	0.000658	CcSEcCtD
Irinotecan—Neutropenia—Epirubicin—testicular cancer	3.3e-05	0.000657	CcSEcCtD
Irinotecan—Abdominal distension—Doxorubicin—testicular cancer	3.28e-05	0.000654	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Epirubicin—testicular cancer	3.28e-05	0.000653	CcSEcCtD
Irinotecan—Stomatitis—Methotrexate—testicular cancer	3.27e-05	0.000652	CcSEcCtD
Irinotecan—Asthenia—Ifosfamide—testicular cancer	3.25e-05	0.000647	CcSEcCtD
Irinotecan—Sweating—Methotrexate—testicular cancer	3.22e-05	0.000642	CcSEcCtD
Irinotecan—Feeling abnormal—Cisplatin—testicular cancer	3.22e-05	0.000641	CcSEcCtD
Irinotecan—Paraesthesia—Etoposide—testicular cancer	3.21e-05	0.00064	CcSEcCtD
Irinotecan—Pancreatitis—Doxorubicin—testicular cancer	3.2e-05	0.000637	CcSEcCtD
Irinotecan—Weight decreased—Epirubicin—testicular cancer	3.19e-05	0.000636	CcSEcCtD
Irinotecan—Dyspnoea—Etoposide—testicular cancer	3.19e-05	0.000635	CcSEcCtD
Irinotecan—Somnolence—Etoposide—testicular cancer	3.18e-05	0.000634	CcSEcCtD
Irinotecan—Angina pectoris—Doxorubicin—testicular cancer	3.18e-05	0.000633	CcSEcCtD
Irinotecan—Pneumonia—Epirubicin—testicular cancer	3.16e-05	0.00063	CcSEcCtD
Irinotecan—Nausea—Bleomycin—testicular cancer	3.15e-05	0.000627	CcSEcCtD
Irinotecan—Vomiting—Dactinomycin—testicular cancer	3.14e-05	0.000626	CcSEcCtD
Irinotecan—Rash—Dactinomycin—testicular cancer	3.12e-05	0.000621	CcSEcCtD
Irinotecan—Decreased appetite—Etoposide—testicular cancer	3.11e-05	0.000619	CcSEcCtD
Irinotecan—Diarrhoea—Ifosfamide—testicular cancer	3.1e-05	0.000617	CcSEcCtD
Irinotecan—Renal failure—Epirubicin—testicular cancer	3.09e-05	0.000616	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Etoposide—testicular cancer	3.09e-05	0.000615	CcSEcCtD
Irinotecan—Body temperature increased—Cisplatin—testicular cancer	3.09e-05	0.000615	CcSEcCtD
Irinotecan—Fatigue—Etoposide—testicular cancer	3.08e-05	0.000614	CcSEcCtD
Irinotecan—Stomatitis—Epirubicin—testicular cancer	3.06e-05	0.000611	CcSEcCtD
Irinotecan—Jaundice—Epirubicin—testicular cancer	3.06e-05	0.000611	CcSEcCtD
Irinotecan—Constipation—Etoposide—testicular cancer	3.06e-05	0.000609	CcSEcCtD
Irinotecan—Pain—Etoposide—testicular cancer	3.06e-05	0.000609	CcSEcCtD
Irinotecan—Neutropenia—Doxorubicin—testicular cancer	3.05e-05	0.000608	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Doxorubicin—testicular cancer	3.03e-05	0.000604	CcSEcCtD
Irinotecan—Haemoglobin—Methotrexate—testicular cancer	3.03e-05	0.000604	CcSEcCtD
Irinotecan—Haemorrhage—Methotrexate—testicular cancer	3.01e-05	0.000601	CcSEcCtD
Irinotecan—Sweating—Epirubicin—testicular cancer	3.01e-05	0.0006	CcSEcCtD
Irinotecan—Dizziness—Ifosfamide—testicular cancer	2.99e-05	0.000597	CcSEcCtD
Irinotecan—Weight decreased—Doxorubicin—testicular cancer	2.95e-05	0.000588	CcSEcCtD
Irinotecan—Feeling abnormal—Etoposide—testicular cancer	2.95e-05	0.000587	CcSEcCtD
Irinotecan—Nausea—Dactinomycin—testicular cancer	2.93e-05	0.000585	CcSEcCtD
Irinotecan—Pneumonia—Doxorubicin—testicular cancer	2.92e-05	0.000583	CcSEcCtD
Irinotecan—Gastrointestinal pain—Etoposide—testicular cancer	2.92e-05	0.000583	CcSEcCtD
Irinotecan—Visual impairment—Methotrexate—testicular cancer	2.91e-05	0.000579	CcSEcCtD
Irinotecan—Vomiting—Ifosfamide—testicular cancer	2.88e-05	0.000574	CcSEcCtD
Irinotecan—Hypersensitivity—Cisplatin—testicular cancer	2.88e-05	0.000573	CcSEcCtD
Irinotecan—Bradycardia—Epirubicin—testicular cancer	2.87e-05	0.000572	CcSEcCtD
Irinotecan—Renal failure—Doxorubicin—testicular cancer	2.86e-05	0.00057	CcSEcCtD
Irinotecan—Rash—Ifosfamide—testicular cancer	2.85e-05	0.000569	CcSEcCtD
Irinotecan—Dermatitis—Ifosfamide—testicular cancer	2.85e-05	0.000568	CcSEcCtD
Irinotecan—Haemoglobin—Epirubicin—testicular cancer	2.84e-05	0.000565	CcSEcCtD
Irinotecan—Jaundice—Doxorubicin—testicular cancer	2.83e-05	0.000565	CcSEcCtD
Irinotecan—Stomatitis—Doxorubicin—testicular cancer	2.83e-05	0.000565	CcSEcCtD
Irinotecan—Rhinitis—Epirubicin—testicular cancer	2.83e-05	0.000564	CcSEcCtD
Irinotecan—Abdominal pain—Etoposide—testicular cancer	2.83e-05	0.000563	CcSEcCtD
Irinotecan—Body temperature increased—Etoposide—testicular cancer	2.83e-05	0.000563	CcSEcCtD
Irinotecan—Haemorrhage—Epirubicin—testicular cancer	2.82e-05	0.000562	CcSEcCtD
Irinotecan—Asthenia—Cisplatin—testicular cancer	2.8e-05	0.000558	CcSEcCtD
Irinotecan—Cardiac disorder—Methotrexate—testicular cancer	2.8e-05	0.000558	CcSEcCtD
Irinotecan—Sweating—Doxorubicin—testicular cancer	2.79e-05	0.000556	CcSEcCtD
Irinotecan—Connective tissue disorder—Epirubicin—testicular cancer	2.77e-05	0.000553	CcSEcCtD
Irinotecan—Angiopathy—Methotrexate—testicular cancer	2.74e-05	0.000545	CcSEcCtD
Irinotecan—Immune system disorder—Methotrexate—testicular cancer	2.72e-05	0.000543	CcSEcCtD
Irinotecan—Visual impairment—Epirubicin—testicular cancer	2.72e-05	0.000542	CcSEcCtD
Irinotecan—Mediastinal disorder—Methotrexate—testicular cancer	2.72e-05	0.000541	CcSEcCtD
Irinotecan—Chills—Methotrexate—testicular cancer	2.71e-05	0.000539	CcSEcCtD
Irinotecan—Nausea—Ifosfamide—testicular cancer	2.69e-05	0.000536	CcSEcCtD
Irinotecan—Diarrhoea—Cisplatin—testicular cancer	2.67e-05	0.000532	CcSEcCtD
Irinotecan—Alopecia—Methotrexate—testicular cancer	2.66e-05	0.000531	CcSEcCtD
Irinotecan—Bradycardia—Doxorubicin—testicular cancer	2.66e-05	0.00053	CcSEcCtD
Irinotecan—Hypersensitivity—Etoposide—testicular cancer	2.63e-05	0.000525	CcSEcCtD
Irinotecan—Haemoglobin—Doxorubicin—testicular cancer	2.62e-05	0.000523	CcSEcCtD
Irinotecan—Cardiac disorder—Epirubicin—testicular cancer	2.62e-05	0.000522	CcSEcCtD
Irinotecan—Flushing—Epirubicin—testicular cancer	2.62e-05	0.000522	CcSEcCtD
Irinotecan—Rhinitis—Doxorubicin—testicular cancer	2.62e-05	0.000522	CcSEcCtD
Irinotecan—Haemorrhage—Doxorubicin—testicular cancer	2.61e-05	0.00052	CcSEcCtD
Irinotecan—Asthenia—Etoposide—testicular cancer	2.57e-05	0.000511	CcSEcCtD
Irinotecan—Connective tissue disorder—Doxorubicin—testicular cancer	2.57e-05	0.000511	CcSEcCtD
Irinotecan—Angiopathy—Epirubicin—testicular cancer	2.56e-05	0.00051	CcSEcCtD
Irinotecan—Immune system disorder—Epirubicin—testicular cancer	2.55e-05	0.000508	CcSEcCtD
Irinotecan—Mediastinal disorder—Epirubicin—testicular cancer	2.54e-05	0.000507	CcSEcCtD
Irinotecan—Back pain—Methotrexate—testicular cancer	2.54e-05	0.000506	CcSEcCtD
Irinotecan—Chills—Epirubicin—testicular cancer	2.53e-05	0.000505	CcSEcCtD
Irinotecan—Arrhythmia—Epirubicin—testicular cancer	2.52e-05	0.000502	CcSEcCtD
Irinotecan—Visual impairment—Doxorubicin—testicular cancer	2.52e-05	0.000501	CcSEcCtD
Irinotecan—Alopecia—Epirubicin—testicular cancer	2.49e-05	0.000497	CcSEcCtD
Irinotecan—Vomiting—Cisplatin—testicular cancer	2.48e-05	0.000495	CcSEcCtD
Irinotecan—Rash—Cisplatin—testicular cancer	2.46e-05	0.00049	CcSEcCtD
Irinotecan—Dermatitis—Cisplatin—testicular cancer	2.46e-05	0.00049	CcSEcCtD
Irinotecan—Diarrhoea—Etoposide—testicular cancer	2.45e-05	0.000488	CcSEcCtD
Irinotecan—Ill-defined disorder—Methotrexate—testicular cancer	2.44e-05	0.000485	CcSEcCtD
Irinotecan—Anaemia—Methotrexate—testicular cancer	2.43e-05	0.000483	CcSEcCtD
Irinotecan—Flushing—Doxorubicin—testicular cancer	2.42e-05	0.000483	CcSEcCtD
Irinotecan—Cardiac disorder—Doxorubicin—testicular cancer	2.42e-05	0.000483	CcSEcCtD
Irinotecan—Flatulence—Epirubicin—testicular cancer	2.42e-05	0.000482	CcSEcCtD
Irinotecan—Back pain—Epirubicin—testicular cancer	2.38e-05	0.000473	CcSEcCtD
Irinotecan—Angiopathy—Doxorubicin—testicular cancer	2.37e-05	0.000472	CcSEcCtD
Irinotecan—Malaise—Methotrexate—testicular cancer	2.37e-05	0.000472	CcSEcCtD
Irinotecan—Dizziness—Etoposide—testicular cancer	2.36e-05	0.000471	CcSEcCtD
Irinotecan—Muscle spasms—Epirubicin—testicular cancer	2.36e-05	0.000471	CcSEcCtD
Irinotecan—Immune system disorder—Doxorubicin—testicular cancer	2.36e-05	0.00047	CcSEcCtD
Irinotecan—Vertigo—Methotrexate—testicular cancer	2.36e-05	0.00047	CcSEcCtD
Irinotecan—Mediastinal disorder—Doxorubicin—testicular cancer	2.35e-05	0.000469	CcSEcCtD
Irinotecan—Leukopenia—Methotrexate—testicular cancer	2.35e-05	0.000468	CcSEcCtD
Irinotecan—Chills—Doxorubicin—testicular cancer	2.34e-05	0.000467	CcSEcCtD
Irinotecan—Arrhythmia—Doxorubicin—testicular cancer	2.33e-05	0.000465	CcSEcCtD
Irinotecan—Nausea—Cisplatin—testicular cancer	2.32e-05	0.000462	CcSEcCtD
Irinotecan—Alopecia—Doxorubicin—testicular cancer	2.31e-05	0.00046	CcSEcCtD
Irinotecan—Cough—Methotrexate—testicular cancer	2.29e-05	0.000456	CcSEcCtD
Irinotecan—Ill-defined disorder—Epirubicin—testicular cancer	2.28e-05	0.000454	CcSEcCtD
Irinotecan—Vomiting—Etoposide—testicular cancer	2.27e-05	0.000453	CcSEcCtD
Irinotecan—Anaemia—Epirubicin—testicular cancer	2.27e-05	0.000452	CcSEcCtD
Irinotecan—Rash—Etoposide—testicular cancer	2.25e-05	0.000449	CcSEcCtD
Irinotecan—Dermatitis—Etoposide—testicular cancer	2.25e-05	0.000449	CcSEcCtD
Irinotecan—Headache—Etoposide—testicular cancer	2.24e-05	0.000446	CcSEcCtD
Irinotecan—Flatulence—Doxorubicin—testicular cancer	2.24e-05	0.000446	CcSEcCtD
Irinotecan—Malaise—Epirubicin—testicular cancer	2.21e-05	0.000441	CcSEcCtD
Irinotecan—Discomfort—Methotrexate—testicular cancer	2.21e-05	0.00044	CcSEcCtD
Irinotecan—Vertigo—Epirubicin—testicular cancer	2.21e-05	0.00044	CcSEcCtD
Irinotecan—Syncope—Epirubicin—testicular cancer	2.2e-05	0.000439	CcSEcCtD
Irinotecan—Leukopenia—Epirubicin—testicular cancer	2.2e-05	0.000438	CcSEcCtD
Irinotecan—Back pain—Doxorubicin—testicular cancer	2.2e-05	0.000438	CcSEcCtD
Irinotecan—Muscle spasms—Doxorubicin—testicular cancer	2.18e-05	0.000435	CcSEcCtD
Irinotecan—Confusional state—Methotrexate—testicular cancer	2.16e-05	0.00043	CcSEcCtD
Irinotecan—Loss of consciousness—Epirubicin—testicular cancer	2.16e-05	0.00043	CcSEcCtD
Irinotecan—Cough—Epirubicin—testicular cancer	2.14e-05	0.000427	CcSEcCtD
Irinotecan—Anaphylactic shock—Methotrexate—testicular cancer	2.14e-05	0.000427	CcSEcCtD
Irinotecan—Infection—Methotrexate—testicular cancer	2.13e-05	0.000424	CcSEcCtD
Irinotecan—Nausea—Etoposide—testicular cancer	2.12e-05	0.000423	CcSEcCtD
Irinotecan—Hypertension—Epirubicin—testicular cancer	2.12e-05	0.000423	CcSEcCtD
Irinotecan—Ill-defined disorder—Doxorubicin—testicular cancer	2.11e-05	0.00042	CcSEcCtD
Irinotecan—Nervous system disorder—Methotrexate—testicular cancer	2.1e-05	0.000419	CcSEcCtD
Irinotecan—Anaemia—Doxorubicin—testicular cancer	2.1e-05	0.000419	CcSEcCtD
Irinotecan—Thrombocytopenia—Methotrexate—testicular cancer	2.1e-05	0.000418	CcSEcCtD
Irinotecan—Hyperhidrosis—Methotrexate—testicular cancer	2.07e-05	0.000413	CcSEcCtD
Irinotecan—Discomfort—Epirubicin—testicular cancer	2.07e-05	0.000412	CcSEcCtD
Irinotecan—Malaise—Doxorubicin—testicular cancer	2.05e-05	0.000408	CcSEcCtD
Irinotecan—Vertigo—Doxorubicin—testicular cancer	2.04e-05	0.000407	CcSEcCtD
Irinotecan—Anorexia—Methotrexate—testicular cancer	2.04e-05	0.000407	CcSEcCtD
Irinotecan—Syncope—Doxorubicin—testicular cancer	2.04e-05	0.000406	CcSEcCtD
Irinotecan—Leukopenia—Doxorubicin—testicular cancer	2.03e-05	0.000405	CcSEcCtD
Irinotecan—Confusional state—Epirubicin—testicular cancer	2.02e-05	0.000403	CcSEcCtD
Irinotecan—Anaphylactic shock—Epirubicin—testicular cancer	2e-05	0.000399	CcSEcCtD
Irinotecan—Oedema—Epirubicin—testicular cancer	2e-05	0.000399	CcSEcCtD
Irinotecan—Hypotension—Methotrexate—testicular cancer	2e-05	0.000399	CcSEcCtD
Irinotecan—Loss of consciousness—Doxorubicin—testicular cancer	2e-05	0.000398	CcSEcCtD
Irinotecan—Infection—Epirubicin—testicular cancer	1.99e-05	0.000397	CcSEcCtD
Irinotecan—Cough—Doxorubicin—testicular cancer	1.98e-05	0.000395	CcSEcCtD
Irinotecan—Shock—Epirubicin—testicular cancer	1.97e-05	0.000393	CcSEcCtD
Irinotecan—Nervous system disorder—Epirubicin—testicular cancer	1.97e-05	0.000392	CcSEcCtD
Irinotecan—Thrombocytopenia—Epirubicin—testicular cancer	1.96e-05	0.000391	CcSEcCtD
Irinotecan—Hypertension—Doxorubicin—testicular cancer	1.96e-05	0.000391	CcSEcCtD
Irinotecan—Hyperhidrosis—Epirubicin—testicular cancer	1.94e-05	0.000386	CcSEcCtD
Irinotecan—Insomnia—Methotrexate—testicular cancer	1.94e-05	0.000386	CcSEcCtD
Irinotecan—Paraesthesia—Methotrexate—testicular cancer	1.92e-05	0.000383	CcSEcCtD
Irinotecan—Discomfort—Doxorubicin—testicular cancer	1.91e-05	0.000381	CcSEcCtD
Irinotecan—Anorexia—Epirubicin—testicular cancer	1.91e-05	0.000381	CcSEcCtD
Irinotecan—Dyspnoea—Methotrexate—testicular cancer	1.91e-05	0.000381	CcSEcCtD
Irinotecan—Somnolence—Methotrexate—testicular cancer	1.9e-05	0.000379	CcSEcCtD
Irinotecan—Dyspepsia—Methotrexate—testicular cancer	1.89e-05	0.000376	CcSEcCtD
Irinotecan—Hypotension—Epirubicin—testicular cancer	1.87e-05	0.000373	CcSEcCtD
Irinotecan—Confusional state—Doxorubicin—testicular cancer	1.87e-05	0.000373	CcSEcCtD
Irinotecan—Decreased appetite—Methotrexate—testicular cancer	1.86e-05	0.000371	CcSEcCtD
Irinotecan—Anaphylactic shock—Doxorubicin—testicular cancer	1.85e-05	0.00037	CcSEcCtD
Irinotecan—Oedema—Doxorubicin—testicular cancer	1.85e-05	0.00037	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Methotrexate—testicular cancer	1.85e-05	0.000369	CcSEcCtD
Irinotecan—Fatigue—Methotrexate—testicular cancer	1.85e-05	0.000368	CcSEcCtD
Irinotecan—Infection—Doxorubicin—testicular cancer	1.84e-05	0.000367	CcSEcCtD
Irinotecan—Pain—Methotrexate—testicular cancer	1.83e-05	0.000365	CcSEcCtD
Irinotecan—Shock—Doxorubicin—testicular cancer	1.82e-05	0.000364	CcSEcCtD
Irinotecan—Nervous system disorder—Doxorubicin—testicular cancer	1.82e-05	0.000362	CcSEcCtD
Irinotecan—Thrombocytopenia—Doxorubicin—testicular cancer	1.82e-05	0.000362	CcSEcCtD
Irinotecan—Insomnia—Epirubicin—testicular cancer	1.81e-05	0.000361	CcSEcCtD
Irinotecan—Paraesthesia—Epirubicin—testicular cancer	1.8e-05	0.000359	CcSEcCtD
Irinotecan—Hyperhidrosis—Doxorubicin—testicular cancer	1.79e-05	0.000357	CcSEcCtD
Irinotecan—Dyspnoea—Epirubicin—testicular cancer	1.79e-05	0.000356	CcSEcCtD
Irinotecan—Somnolence—Epirubicin—testicular cancer	1.78e-05	0.000355	CcSEcCtD
Irinotecan—Anorexia—Doxorubicin—testicular cancer	1.77e-05	0.000352	CcSEcCtD
Irinotecan—Feeling abnormal—Methotrexate—testicular cancer	1.77e-05	0.000352	CcSEcCtD
Irinotecan—Dyspepsia—Epirubicin—testicular cancer	1.76e-05	0.000352	CcSEcCtD
Irinotecan—Gastrointestinal pain—Methotrexate—testicular cancer	1.75e-05	0.000349	CcSEcCtD
Irinotecan—Decreased appetite—Epirubicin—testicular cancer	1.74e-05	0.000347	CcSEcCtD
Irinotecan—Hypotension—Doxorubicin—testicular cancer	1.73e-05	0.000345	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Epirubicin—testicular cancer	1.73e-05	0.000345	CcSEcCtD
Irinotecan—Fatigue—Epirubicin—testicular cancer	1.73e-05	0.000344	CcSEcCtD
Irinotecan—Pain—Epirubicin—testicular cancer	1.71e-05	0.000342	CcSEcCtD
Irinotecan—Constipation—Epirubicin—testicular cancer	1.71e-05	0.000342	CcSEcCtD
Irinotecan—Body temperature increased—Methotrexate—testicular cancer	1.69e-05	0.000337	CcSEcCtD
Irinotecan—Abdominal pain—Methotrexate—testicular cancer	1.69e-05	0.000337	CcSEcCtD
Irinotecan—Insomnia—Doxorubicin—testicular cancer	1.68e-05	0.000334	CcSEcCtD
Irinotecan—Paraesthesia—Doxorubicin—testicular cancer	1.67e-05	0.000332	CcSEcCtD
Irinotecan—Dyspnoea—Doxorubicin—testicular cancer	1.65e-05	0.00033	CcSEcCtD
Irinotecan—Feeling abnormal—Epirubicin—testicular cancer	1.65e-05	0.000329	CcSEcCtD
Irinotecan—Somnolence—Doxorubicin—testicular cancer	1.65e-05	0.000329	CcSEcCtD
Irinotecan—Gastrointestinal pain—Epirubicin—testicular cancer	1.64e-05	0.000327	CcSEcCtD
Irinotecan—Dyspepsia—Doxorubicin—testicular cancer	1.63e-05	0.000325	CcSEcCtD
Irinotecan—Decreased appetite—Doxorubicin—testicular cancer	1.61e-05	0.000321	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.6e-05	0.000319	CcSEcCtD
Irinotecan—Fatigue—Doxorubicin—testicular cancer	1.6e-05	0.000319	CcSEcCtD
Irinotecan—Pain—Doxorubicin—testicular cancer	1.59e-05	0.000316	CcSEcCtD
Irinotecan—Constipation—Doxorubicin—testicular cancer	1.59e-05	0.000316	CcSEcCtD
Irinotecan—Body temperature increased—Epirubicin—testicular cancer	1.58e-05	0.000316	CcSEcCtD
Irinotecan—Abdominal pain—Epirubicin—testicular cancer	1.58e-05	0.000316	CcSEcCtD
Irinotecan—Hypersensitivity—Methotrexate—testicular cancer	1.58e-05	0.000314	CcSEcCtD
Irinotecan—Asthenia—Methotrexate—testicular cancer	1.54e-05	0.000306	CcSEcCtD
Irinotecan—Feeling abnormal—Doxorubicin—testicular cancer	1.53e-05	0.000305	CcSEcCtD
Irinotecan—Gastrointestinal pain—Doxorubicin—testicular cancer	1.52e-05	0.000302	CcSEcCtD
Irinotecan—Hypersensitivity—Epirubicin—testicular cancer	1.48e-05	0.000294	CcSEcCtD
Irinotecan—Body temperature increased—Doxorubicin—testicular cancer	1.47e-05	0.000292	CcSEcCtD
Irinotecan—Abdominal pain—Doxorubicin—testicular cancer	1.47e-05	0.000292	CcSEcCtD
Irinotecan—Diarrhoea—Methotrexate—testicular cancer	1.47e-05	0.000292	CcSEcCtD
Irinotecan—Asthenia—Epirubicin—testicular cancer	1.44e-05	0.000287	CcSEcCtD
Irinotecan—Dizziness—Methotrexate—testicular cancer	1.42e-05	0.000282	CcSEcCtD
Irinotecan—Diarrhoea—Epirubicin—testicular cancer	1.37e-05	0.000273	CcSEcCtD
Irinotecan—Hypersensitivity—Doxorubicin—testicular cancer	1.37e-05	0.000272	CcSEcCtD
Irinotecan—Vomiting—Methotrexate—testicular cancer	1.36e-05	0.000271	CcSEcCtD
Irinotecan—Rash—Methotrexate—testicular cancer	1.35e-05	0.000269	CcSEcCtD
Irinotecan—Dermatitis—Methotrexate—testicular cancer	1.35e-05	0.000269	CcSEcCtD
Irinotecan—Headache—Methotrexate—testicular cancer	1.34e-05	0.000267	CcSEcCtD
Irinotecan—Asthenia—Doxorubicin—testicular cancer	1.33e-05	0.000265	CcSEcCtD
Irinotecan—Dizziness—Epirubicin—testicular cancer	1.33e-05	0.000264	CcSEcCtD
Irinotecan—Vomiting—Epirubicin—testicular cancer	1.27e-05	0.000254	CcSEcCtD
Irinotecan—Nausea—Methotrexate—testicular cancer	1.27e-05	0.000254	CcSEcCtD
Irinotecan—Diarrhoea—Doxorubicin—testicular cancer	1.27e-05	0.000253	CcSEcCtD
Irinotecan—Rash—Epirubicin—testicular cancer	1.26e-05	0.000252	CcSEcCtD
Irinotecan—Dermatitis—Epirubicin—testicular cancer	1.26e-05	0.000252	CcSEcCtD
Irinotecan—Headache—Epirubicin—testicular cancer	1.26e-05	0.00025	CcSEcCtD
Irinotecan—Dizziness—Doxorubicin—testicular cancer	1.23e-05	0.000244	CcSEcCtD
Irinotecan—Nausea—Epirubicin—testicular cancer	1.19e-05	0.000237	CcSEcCtD
Irinotecan—Vomiting—Doxorubicin—testicular cancer	1.18e-05	0.000235	CcSEcCtD
Irinotecan—Rash—Doxorubicin—testicular cancer	1.17e-05	0.000233	CcSEcCtD
Irinotecan—Dermatitis—Doxorubicin—testicular cancer	1.17e-05	0.000233	CcSEcCtD
Irinotecan—Headache—Doxorubicin—testicular cancer	1.16e-05	0.000232	CcSEcCtD
Irinotecan—Nausea—Doxorubicin—testicular cancer	1.1e-05	0.00022	CcSEcCtD
